-
In what is getting to be a familiar, tragic refrain, the improper use of single-dose vials recently resulted in patients at pain clinics in Arizona and Delaware acquiring serious bacterial infections that were "completely preventable," the Centers for Disease Control and Prevention reports.
-
The Centers for Disease Control and Prevention is trying to overcome some stubborn myths and misperceptions about single-dose vials including the following, which the agency refuted with the current facts.
-
A Centers for Medicare & Medicaid Services draft infection control survey expected to be finalized for use in hospitals next year could lead to increased support and appreciation for the challenges faced by central services departments, says Rose Seavey, RN, BS, MBA, CNOR, CRCST, CSPDT, President/CEO of Seavey Healthcare Consulting, Inc., in Arvada, CO.
-
Infective endocarditis (IE) continues to be a serious illness with high morbidity and mortality despite modern therapies.
-
-
On 15 May the FDA Center for Biologics Evaluation and Research/Office of Blood Research and Review (CBER/OBRR) granted market clearance to the OraQuick in-home HIV-1/2 antibody test based on the recommendation of the Blood Products Advisory Committee.
-
The U.S. Food and Drug Administration (FDA) recently issued an alert on the potential risk of non-convulsive status epilepticus associated with the use of cefepime, a broad spectrum fourth generation cephalosporin.
-
FoodNet is an active surveillance program that collects data on 9 laboratory-confirmed pathogens from 10 sites in the United States: 7 states (Connecticut, Georgia, Maryland, Minnesota, New Mexico, Oregon, and Tennessee) and certain counties in California, Colorado, and New York.
-
In this issue: Lorcaserin for weight loss; statins and fatigue; treatment-resistant gonorrhea; hydrocodone classification changes; USPSTF recommendations; and FDA actions.
-
A total of 1745 infants from 17 sites in Brazil (70.1%), South Africa (27.4%), Argentina (1.6%) and the United States (0.8%) born to women with a peripartum diagnosis of HIV type I infection were randomized within 48 hours of birth to receive one of three six-week postpartum antiretroviral regimens.
